Candel Therapeutics to Showcase Glioblastoma Data at Industry Summit
Event summary
- Candel Therapeutics' CSO Francesca Barone to present data on linoserpaturev (CAN-3110) at the 7th Annual Glioblastoma Drug Development Summit, Feb. 17-19, 2026.
- Focus on biomarker-driven clinical development and patient stratification in glioblastoma trials.
- Linoserpaturev previously showed improved median overall survival in recurrent high-grade glioma (rHGG) trials.
- CAN-3110 has received Fast Track and Orphan Drug Designations from the FDA for rHGG treatment.
The big picture
Candel Therapeutics' participation in the Glioblastoma Drug Development Summit underscores the growing emphasis on biomarker-driven approaches in oncology. The company's focus on recurrent high-grade glioma aligns with broader industry trends toward precision medicine in hard-to-treat cancers. With multiple regulatory designations already secured for linoserpaturev, Candel appears positioned to capitalize on the demand for novel immunotherapies in glioblastoma.
What we're watching
- Clinical Validation
- Whether linoserpaturev's observed survival benefits in rHGG can be replicated in larger, controlled studies.
- Regulatory Pathway
- The pace at which CAN-3110 advances through clinical trials given its Fast Track and Orphan Drug Designations.
- Competitive Positioning
- How Candel's HSV-based platform differentiates against other oncolytic virus therapies in development.
Related topics